Patent US4761283A successfully refreshed from Google Patents.
US4761283A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Immunogenic conjugates
Assignee: University of Rochester
•
Filing: 1986-03-28
•
Granted: 1988-08-02
•
Expires: 2006-03-28
Abstract
Abstract An immunogenic conjugate which is the reductive amination product of an immunogenic capsular polymer fragment having a reducing end and derived from a bacterial capsular polymer of a bacterial pathogen, and a bacterial toxin or toxoid. The invention also relates to methods for the preparation of the conjugates, a vaccine containing the conjugates which elicits effective levels of anti-capsular polymer antibodies in humans. Also disclosed are methods for inducing active immunization against systemic infection in young mammals caused by bacterial pathogens comprising the administration of an immunogenic amount of the above-described conjugate.
Inventors
- 👤 Porter W. Anderson
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-23 16:03
CPC Classifications
A; A61; A61K; A61K39/00; A61K39/385; A61K39/02; A61K39/09; A61K39/092; A61K39/102; A61K47/00; A61K47/50; A61K47/51; A61K47/62; A61K47/64; A61K47/6415; A61K47/646; A61K2039/60; A61K2039/6031; A61K2039/6037; Y; Y10; Y10S; Y10S424/00; Y10S424/831; Y10S424/832
Claims Analysis
Total Claims: 37
Claim 1
Independent Claim
52 words
An immunogenic conjugate, comprising: the reductive amination product of a capsular polymer fragment having a reducing end and derived from the capsular polymer of a bacterial pathogen selected from the group consisting of Haemophilus influenzae type b, Escherichia coli, Neisseria meningitidis and Streptococcus pneumoniae, and the diptheria toxin protein CRM 197 .
Claim 2
Dependent Claim
52 words
An immunogenic conjugate, comprising: the reductive amination product of a capsular polymer fragment having a reducing end and derived from the capsular polymer of a bacterial pathogen selected from the group consisting of Haemophilus influenzae type b, Escherichia coli, Neisseria meningitidis and Streptococcus pneumoniae, and the diptheria toxin protein CRM 197 .
Claim 3
Dependent Claim
21 words
The immunogenic conjugate of claim 1, wherein the capsular polymer is immunogenic in mature humans and less immunogenic in infant humans.
Claim 4
Dependent Claim
18 words
The immunogenic conjugate of claim 1, wherein the reductive amination is performed in the presence of cyanoborohydride anions.
Claim 5
Dependent Claim
15 words
The immunogenic conjugate of claim 1, wherein the bacterial pathogen is Haemophilus influenzae type b.
Claim 6
Dependent Claim
13 words
The immunogenic conjugate of claim 1, wherein the bacterial pathogen is Escherichia coli.
Claim 7
Dependent Claim
13 words
The immunogenic conjugate of claim 1, wherein the bacterial pathogen is Neisseria meningitidis.
Claim 8
Dependent Claim
15 words
The immunogenic conjugate of claim 1, wherein the bacterial pathogen is Neisseria meningitidis serogroup A.
Claim 9
Dependent Claim
15 words
The immunogenic conjugate of claim 1, wherein the bacterial pathogen is Neisseria meningitidis serogroup C.
Claim 10
Dependent Claim
13 words
The immunogenic conjugate of claim 1, wherein the bacterial pathogen is Streptococcus pneumoniae.
Claim 11
Dependent Claim
15 words
The immunogenic conjugate of claim 1, wherein the bacterial pathogen is Streptococcus pneumoniae serotype 3.
Claim 12
Dependent Claim
15 words
The immunogenic conjugate of claim 1, wherein the bacterial pathogen is Streptococcus pneumoniae serotype 6.
Claim 13
Dependent Claim
15 words
The immunogenic conjugate of claim 1, wherein the bacterial pathogen is Streptococcus pneumoniae serotype 12.
Claim 14
Dependent Claim
15 words
The immunogenic conjugate of claim 1, wherein the bacterial pathogen is Streptococcus pneumoniae serotype 14.
Claim 15
Dependent Claim
15 words
The immunogenic conjugate of claim 1, wherein the bacterial pathogen is Streptococcus pneumoniae serotype 19.
Claim 16
Dependent Claim
15 words
The immunogenic conjugate of claim 1, wherein the bacterial pathogen is Streptococcus pneumoniae serotype 23.
Claim 17
Dependent Claim
15 words
The immunogenic conjugate of claim 1, wherein the bacterial pathogen is Streptococcus pneumoniae serotype 51.
Claim 18
Dependent Claim
18 words
The immunogenic conjugate of claim 1, wherein the fragment is derived from the capsular polymer by oxidative cleavage.
Claim 19
Dependent Claim
17 words
The immunogenic conjugate of claim 1, wherein the fragment is derived from the capsular polymer by periodate.
Claim 20
Dependent Claim
21 words
The immunogenic conjugate of claim 1, wherein the fragment is derived from the capsular polymer by hydrolysis of a glycosidic linkage.
Claim 21
Dependent Claim
12 words
The immunogenic conjugate of claim 19, wherein the hydrolysis is accomplished enzymatically.
Claim 22
Dependent Claim
12 words
The immunogenic conjugate of claim 19, wherein the hydrolysis is accomplished chemically.
Claim 23
Dependent Claim
13 words
The immunogenic conjugate of claim 19, wherein the hydrolysis is accomplished by acid.
Claim 24
Dependent Claim
22 words
The immunogenic conjugate of claim 4, wherein the fragment elutes on a column of Bio-Gel P-10 at a Ve/Vo ratio of ≦1.08.
Claim 25
Dependent Claim
22 words
The immunogenic conjugate of claim 4, wherein the fragment elutes on a column of Bio-Gel P-10 at a Ve/Vo ratio of 1.09-1.38.
Claim 26
Dependent Claim
22 words
The immunogenic conjugate of claim 4, wherein the fragment elutes on a column of Bio-Gel P-10 at a Ve/Vo ratio of 1.39-1.99.
Claim 27
Dependent Claim
22 words
The immunogenic conjugate of claim 14 wherein the fragment elutes on a column of Bio-Gel P-10 at a Ve/Vo ratio of 2.0-2.4.
Claim 28
Dependent Claim
54 words
An immunogenic conjugate, comprising: a formalin treated reductive amination product of a capsular polymer fragment having a reducing end and derived from the capsular polymer of a bacterial pathogen selected from the group consisting of Haemophilus influenzae type b, Escherichia coli, Neisseria meningitidis and Streptococcus pneumoniae, and the diptheria toxin protein CRM 197 .
Claim 29
Dependent Claim
54 words
An immunogenic conjugate, comprising: a formalin treated reductive amination product of a capsular polymer fragment having a reducing end and derived from the capsular polymer of a bacterial pathogen selected from the group consisting of Haemophilus influenzae type b, Escherichia coli, Neisseria meningitidis and Streptococcus pneumoniae, and the diptheria toxin protein CRM 197 .
Claim 30
Dependent Claim
19 words
A vaccine that elicits effective levels of anti-capsular polymer antibodies in humans, comprising: the immunogenic conjugate of claim 1.
Claim 31
Dependent Claim
23 words
A method for actively immunizing humans bacterial pathogen having a capsular polymer, comprising: administering an effective amount of the vaccine of claim 28.
Claim 32
Dependent Claim
68 words
An immunogenic conjugate of (1) a bacterial capsular polymer fragment having a reducing end, said fragment produced by selective acid hydrolysis of a capsular polymer obtained from a bacterial pathogen selected from the group consisting of selected from the group consisting of Haemophilus influenzae type b, Escherichia coli, Neisseria meningitidis and Streptococcus pneumoniae, without significant destruction of antigenic specificity, and (2) the diphtheria toxin protein CRM 197 .
Claim 33
Dependent Claim
68 words
An immunogenic conjugate of (1) a bacterial capsular polymer fragment having a reducing end, said fragment produced by selective acid hydrolysis of a capsular polymer obtained from a bacterial pathogen selected from the group consisting of selected from the group consisting of Haemophilus influenzae type b, Escherichia coli, Neisseria meningitidis and Streptococcus pneumoniae, without significant destruction of antigenic specificity, and (2) the diphtheria toxin protein CRM 197 .
Claim 34
Dependent Claim
19 words
The immunogenic conjugate of claim 30, wherein the capsular polymer is derived from Streptococcus pneumoniae serotype 6 or 12.
Claim 35
Dependent Claim
31 words
A vaccine that elicits effective levels of anti-polyribosyl ribitol phosphate antibody formations in young warm-blooded mammals comprising an immunogenic amount of the conjugate of claim 1 and a pharmaceutically acceptable carrier.
Claim 36
Dependent Claim
31 words
A vaccine that elicits effective levels of anti-polyribosyl ribitol phosphate antibody formations in young warm-blooded mammals comprising an immunogenic amount of the conjugate of claim 4 and a pharmaceutically acceptable carrier.
Claim 37
Dependent Claim
32 words
A method for inducing active immunization against systemic infection in young warm-blooded mammals caused by the pathogen Haemophilus influenzae type b comprising administering an immunogenic amount of the conjugate of claim 4.
References Cited (Backward Citations)
US4210641A
Cited
US4196192A
Cited
US4220717A
Cited
EP0060129A2
Cited
US4411888A
Cited
US4451446A
Cited
EP0098581A2
Cited
US4496538A
Cited
EP0109688A2
Cited
US4459286A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1991-08-02 | 1992-02-01 | 1992-08-02 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1995-08-02 | 1996-02-01 | 1996-08-02 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1999-08-02 | 2000-02-01 | 2000-08-02 | $7700.00 | Window Closed / Lapsed |